Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zynerba Pharmaceuticals, Inc. - Common Stock (NQ: ZYNE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zynerba Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Cannabis Stock Movers For August 3, 2023
Via Benzinga
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
Annual Meeting to Reconvene on August 11, 2023 at 9:00 a.m. EDT 
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 116 companies set new 52-week lows. 
Via Benzinga
Marijuana Stock Movers For August 2, 2023
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cannabis Stock Gainers And Losers From July 18, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 14, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Marijuana Stock Movers For July 12, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 11, 2023
Via Benzinga
Cannabis Stock Movers For July 10, 2023
Via Benzinga
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Why Theriva Biologics Are Trading Higher By Over 76%; Here Are 20 Stocks Moving Premarket
Gainers Theriva Biologics, Inc. (NYSE: TOVX) shares surged 76.4% to $1.46 in pre-market trading after the company said Orphan Drug Designation was granted by the U.S. Food and Drug Administration for... 
Via Benzinga
Why American Equity Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on Tuesday morning! 
Via InvestorPlace
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the first quarter ended March 31, 2023, revealing research and development expenses were $7.1 million for the first quarter... 
Via Benzinga
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 345 companies set new 52-week lows. 
Via Benzinga
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the fourth quarter and full year ended December 31, 2022, revealing research and development expenses were $21.1 million for... 
Via Benzinga
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue. 
Via Benzinga
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 497 companies set new 52-week lows. 
Via Benzinga
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.